Universal Beteiligungs und Servicegesellschaft mbH Sells 3,441 Shares of Illumina, Inc. (NASDAQ:ILMN)

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 220,412 shares of the life sciences company's stock after selling 3,441 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of Illumina worth $17,487,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Capital World Investors lifted its holdings in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. WCM Investment Management LLC lifted its holdings in Illumina by 1.2% during the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after purchasing an additional 49,156 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Illumina by 52.1% during the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after purchasing an additional 996,589 shares in the last quarter. Norges Bank purchased a new position in Illumina during the fourth quarter valued at $228,714,000. Finally, Northern Trust Corp lifted its holdings in Illumina by 26.9% during the fourth quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after purchasing an additional 349,878 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ILMN shares. Citigroup downgraded shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their price objective for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Morgan Stanley decreased their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research note on Friday, July 11th. Barclays reissued an "underweight" rating and issued a $85.00 price target (up from $77.00) on shares of Illumina in a research note on Tuesday, June 24th. Finally, Guggenheim decreased their price target on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Illumina has a consensus rating of "Hold" and a consensus price target of $125.89.

Illumina Price Performance

NASDAQ:ILMN traded up $0.74 during mid-day trading on Monday, reaching $110.04. 548,068 shares of the stock were exchanged, compared to its average volume of 2,388,506. The business has a fifty day moving average price of $91.50 and a 200 day moving average price of $93.45. The firm has a market capitalization of $17.42 billion, a PE ratio of -18.15, a PEG ratio of 2.14 and a beta of 1.36. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter last year, the business posted $0.98 EPS. Illumina's revenue was down 1.4% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer owned 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.17% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.